Skip to main content
Caplight Logo









Pilatus Biosciences

Pilatus Biosciences

Private
LausanneHealthcare & Life Scienceshttps://www.pilatusbio.com/

Last Round

Pre Seed

Dec 15, 2025

Total Funding Raised

$14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pilatus Biosciences is a biotechnology company that develops first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints to reprogram the tumor microenvironment for cancer immunotherapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

metabolic checkpointimmunotherapyoncology drugcancer immunotherapybiopharmaceuticalclinical-stage biotechdrug developmentliver cancer treatmentgastrointestinal cancerbiotech startupclinical trialdrug discoverytherapeutic assetsbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pilatus Biosciences Comparables

Compare Pilatus Biosciences with similar companies based on industry and business-model similarity.

Pilatus Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Elixiron Immunotherapeutics
69%
Vigeo Therapeutics
66%
Bristol Myers Squibb
66%

Pilatus Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedDec 15, 2025

Pilatus Biosciences Investors

Notable investors and investment history

Pilatus Biosciences investors
InvestorRounds
Tiger Jade Pebble AcceleratorPre Seed
Cancer Research InstitutePre Seed
Mosaic Venture LabPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 10, 2026

    Grew 30% QoQ, from 10 to 13 employees.

  • Apr 23, 2026

    Monthly visitors increased 37% to 2.6K.

Pilatus Biosciences Filings

Explore SEC and related filing metadata, where available.

Pilatus Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pilatus Biosciences's valuation, stock price, and market status.

Is Pilatus Biosciences a public or private company?

Pilatus Biosciences is a private company.

What is the current stock price of Pilatus Biosciences?

Pilatus Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Pilatus Biosciences worth (valuation)?

Valuation information for Pilatus Biosciences is not publicly available.

Can I buy Pilatus Biosciences stock?

Pilatus Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Pilatus Biosciences's last funding round?

Pilatus Biosciences's most recent funding round was Seed on December 15, 2025.

Who are the main investors in Pilatus Biosciences?

Key investors in Pilatus Biosciences include Cancer Research Institute.

Will Pilatus Biosciences IPO soon?

No public IPO plans have been announced for Pilatus Biosciences.

How can I track Pilatus Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pilatus Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLausanne
Employee Range13
Year Founded2022
Last FundingDec 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?